MARKET

LRMR

LRMR

Larimar Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.99
+0.01
+0.10%
Closed 16:00 07/23 EDT
OPEN
10.03
PREV CLOSE
9.98
HIGH
10.07
LOW
9.56
VOLUME
34.62K
TURNOVER
--
52 WEEK HIGH
25.87
52 WEEK LOW
7.00
MARKET CAP
153.52M
P/E (TTM)
-3.4872
1D
5D
1M
3M
1Y
5Y
Larimar (LRMR) Upgraded to Buy: Here's Why
Zacks.com · 1d ago
J. Alexander’s and Sykes Enterprises See Activist Action
marketwatch.com · 07/10 01:05
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
BALA CYNWYD, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, Presid...
GlobeNewswire · 07/08 20:01
61 Biggest Movers From Yesterday
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.
Benzinga · 07/07 09:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 07/06 16:39
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47. BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 after dropping around 10% on Friday.
Benzinga · 07/06 16:00
Thinking about buying stock in Exela Technologies, Larimar Therapeutics, Marin Software, Provention Bio, or BioLineRx?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, LRMR, MRIN, PRVB, and BLRX.
PR Newswire - PRF · 07/06 14:30
Notable Insider Buys In The Past Week: Asana, Transocean, IPOS, SPACS And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. A couple of special purpose acquisition companies and some initial public offerings prompted notable insider buying this past week.
Benzinga · 07/05 11:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LRMR. Analyze the recent business situations of Larimar Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LRMR stock price target is 30.00 with a high estimate of 30.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 14.40M
% Owned: 93.70%
Shares Outstanding: 15.37M
TypeInstitutionsShares
Increased
10
653.08K
New
16
990.70K
Decreased
15
916.89K
Sold Out
2
868.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/Director
Joseph Truitt
President/Chief Executive Officer/Director
Carole Ben-Maimon
Chief Financial Officer
Michael Celano
Director
Thomas Hamilton
Director
Jonathan Leff
Independent Director
Thomas Daniel
Independent Director
Frank Thomas
No Data
  • All
  • Financials
  • Insiders
More
About LRMR
Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Webull offers kinds of Larimar Therapeutics Inc stock information, including NASDAQ:LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.